Product Code: RP-ID-10294048 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10294048
Market Overview:
Autism Spectrum Disorder Therapeutics Market, By Drug Types (Insomnia Drugs, Selective Serotonin Reuptake Inhibitors, Anticonvulsants, and Antipsychotics), By Indication, By Distribution Channel and Geography (North America, Europe, Asia Pacific, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025
REPORT HIGHLIGHT
The autism spectrum disorder therapeutics market was valued at USD 2.68 billion by 2017, growing with 3.4% CAGR during the forecast period, 2018-2025
Market Dynamics
Autism spectrum disorder includes a class of neuro-developmental disabilities. Some of the prominent disorders that come under the umbrella term of autism spectrum disorder are pervasive personality disorder-not otherwise specified, Asperger’s syndrome, and autism. Autism spectrum disorder therapeutics concerns with various treatment options such as behavioral therapy, which is usually considered as the first-line treatment. Patients are also given pharmacological therapies to help them function properly in their daily lives.
Autism spectrum disorder therapeutics companies are observed to continuously introduce innovative solutions in the global market after receiving approval from regulatory authorities. In April 2019, Finch Therapeutics Group, a US developer of microbial therapies, received FDA’s Fast Track designation for its Full-Spectrum Microbiota therapy. According to the company, the therapy is aimed at treating autism spectrum disorder in children.
The growing number of autism patients is anticipated to increase the demand for autism spectrum disorder therapeutics. Companies are coming up with various novel products and have a number of drugs in the pipeline for autism treatment. Moreover, there has been a rise in the manufacture of generic pharmaceutical products used to treat autism. All of these factors are expected to push the growth of the global autism spectrum disorder therapeutics market. In addition, companies are investing heavily in research and development to introduce new products in the global market. However, tight regulations and policies associated with product approval are foretold to pose a challenge to players operating in the global autism spectrum disorder therapeutics market.
Drug Type Takeaway
The segment of insomnia drugs is projected to exhibit robust growth in the global autism spectrum disorder therapeutics market. In April 2019, the FDA announced that it will require certain prescription insomnia medicine manufacturers to issue a new boxed warning. The announcement comes after the reporting of several cases of deaths and serious injuries caused due to complex sleep behaviors after taking the medicines. Among indication segments, insomnia could secure a significant share of the global market. Analysts expect hospital pharmacies to collect a leading share of the global market, among distribution channels.
Regional Takeaway
Regionally, North America is forecast to show healthier growth in the global autism spectrum disorder therapeutics market because of the rising awareness about autism, increasing incidence of the disorder, and new product development. Europe could be another high-growth regional market gaining from the increase in research and development activities and rising number of autism awareness programs.
Key Players
The global autism spectrum disorder therapeutics market witnesses the presence of top players such as Actavis, Inc., Curemark LLC, Janssen Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Pediatric BioScience, Inc., Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Merck & Co., and Par Sterile Products, LLC.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY DRUG CLASS
Insomnia Drugs
Selective Serotonin Reuptake Inhibitors
Anticonvulsants
Antipsychotics
Others
MARKET, BY INDICATION
Insomnia
Epilepsy
Depression
Hyperactivity and Inattention
Others
MARKET, BY DISTRIBUTION CHANNEL
Hospital Pharmacies
Retail Pharmacies
Others
MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
Related Reports
Proof of Quality & Reliability
